Guided Therapeutics Inc
Guided Therapeutics, Inc., a medical technology company, develops medical devices. It focuses on the marketing and sale of LuViva, an advanced cervical scan non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. Th… Read more
Guided Therapeutics Inc (GTHP) - Total Liabilities
Latest total liabilities as of September 2025: $6.55 Million USD
Based on the latest financial reports, Guided Therapeutics Inc (GTHP) has total liabilities worth $6.55 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Guided Therapeutics Inc - Total Liabilities Trend (2017–2024)
This chart illustrates how Guided Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Guided Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Guided Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ARIP Public Company Limited
BK:ARIP
|
Thailand | ฿51.43 Million |
|
LCC Infotech Limited
NSE:LCCINFOTEC
|
India | ₹47.93 Million |
|
Ambertech Ltd
AU:AMO
|
Australia | AU$30.30 Million |
|
Sin-Kung Logistics Berhad
KLSE:0305
|
Malaysia | RM74.06 Million |
|
C29 Metals Ltd
AU:C29
|
Australia | AU$115.74K |
|
Nova Organic PCL
BK:NV
|
Thailand | ฿104.86 Million |
|
ROYAL GOLD (RG3.SG)
STU:RG3
|
Germany | €250.70 Million |
|
CannBioRx Life Sciences Corp
NASDAQ:ATNFW
|
USA | $5.33 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Guided Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.12 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 7.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Guided Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Guided Therapeutics Inc (2017–2024)
The table below shows the annual total liabilities of Guided Therapeutics Inc from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $6.27 Million | +14.47% |
| 2023-12-31 | $5.47 Million | -12.39% |
| 2022-12-31 | $6.25 Million | -16.51% |
| 2021-12-31 | $7.49 Million | -38.67% |
| 2020-12-31 | $12.21 Million | -32.62% |
| 2019-12-31 | $18.11 Million | +12.80% |
| 2018-12-31 | $16.06 Million | -19.26% |
| 2017-12-31 | $19.89 Million | -- |